Qiagen, HTG Molecular End First Project Under CDx Development Agreement

May 22, 2018

|

NEW YORK (GenomeWeb) – Qiagen has terminated a project with HTG Molecular Diagnostics that is part of a multi-project assay development agreement between the companies, HTG said today in a filing with the US Securities and Exchange Commission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Qiagen, HTG Molecular End First Project Under CDx Development Agreement

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Illumina to Acquire Grail for $8B in Cash and Stock

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sponsorships